Covid-19: The E484K mutation and the risks it poses

@article{Wise2021Covid19TE,
  title={Covid-19: The E484K mutation and the risks it poses},
  author={Jacqui Wise},
  journal={BMJ},
  year={2021},
  volume={372}
}
  • J. Wise
  • Published 5 February 2021
  • Medicine
  • BMJ
The mutation E484K, first identified in the South African SARS-CoV-2 variant, has now been identified in the UK fast-spreading variant, prompting fears the virus is evolving further and could become resistant to vaccines. Jacqui Wise looks at what we know so far 
The viral phoenix: enhanced infectivity and immunity evasion of SARS-CoV-2 variants
TLDR
The new emerging variants of SARS-CoV-2 and why they have enhanced infectivity and possess the ability to evade immunity are described.
The updated strategy to overcome new challenge: Omicron variant (B.1.1.529) pandemic
Abstract The new variant was discovered in South Africa and threatened the word of concerning new pandemic coming from this variant. The Omicron variant likely would spread more easily than the
Determining international spread of novel B.1.1.523 SARS-CoV-2 lineage
TLDR
A set of mutations including 156_158del, E484K and S494P in Spike protein are reported that are known to significantly reduce SARS-CoV-2 neutralization by convalescent and vaccinee sera and are considered as mutations of concern.
Significance of the RBD mutations in the SARS-CoV-2 Omicron: from spike opening to antibody escape and cell attachment
TLDR
While the Omicron RBD escapes most antibodies from prior infections, epitope analysis shows that it harbors sequences with significantly improved antigenicity compared to other variants, suggesting more potent Omicrons-specific neutralizing antibodies.
The ins and outs of SARS-CoV-2 variants of concern (VOCs)
TLDR
New SARS-CoV-2 variants have emerged that are classified as variants of concern (VOC) because they exhibit greater transmissibility, cause more-severe disease, are better able to escape immunity, or cause higher mortality than the original Wuhan strain.
Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
TLDR
Molnupiravir proved to be effective against infections with each of the SARS-CoV-2 variants and therefore may have potential combating current and future emerging VoCs.
COVID-19 disease ( SARS-CoV-2 virus ) 31 MAY 2021 , VERSION 10 1
TLDR
This document is to summarize and interpret key information based on a comprehensive review of the literature, to help overloaded health professionals keep up to date on the subject of COVID-19.
COVID-19 disease ( SARS-CoV-2 virus ) 15 July 2021 , VERSION 11 1
TLDR
This document is to summarize and interpret key information based on a comprehensive review of the literature, to help overloaded health professionals keep up to date on the subject of COVID-19.
SARS-CoV-2 Mutations and their Viral Variants
...
1
2
3
4
5
...